BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does BioNxt Solutions Inc. (BNXTF) operate in?
BioNxt Solutions Inc. belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is BioNxt Solutions Inc. (BNXTF) current stock price?
As of the latest data, BioNxt Solutions Inc. stock price is $0.23, with a previous close of $0.23. BioNxt Solutions Inc. gained $0.01 in the last trading session, representing a 2.87% increase.
What is BioNxt Solutions Inc. (BNXTF) current market capitalization?
BioNxt Solutions Inc. market cap is approximately 31.97 million.
What is BioNxt Solutions Inc. (BNXTF) Earnings Per Share (EPS)?
The trailing EPS is -$0.05.
Does BioNxt Solutions Inc. (BNXTF) pay dividends?
No. BioNxt Solutions Inc. does not pay a dividend.
What is BioNxt Solutions Inc. (BNXTF) beta (volatility) score?
BioNxt Solutions Inc. has a beta of 1.467, suggesting it is more volatile than the market.
